Advertisement
Canada markets open in 4 hours 39 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7315
    +0.0017 (+0.24%)
     

  • CRUDE OIL

    83.15
    +0.34 (+0.41%)
     

  • Bitcoin CAD

    87,165.92
    -3,922.60 (-4.31%)
     

  • CMC Crypto 200

    1,360.93
    -21.64 (-1.56%)
     

  • GOLD FUTURES

    2,339.80
    +1.40 (+0.06%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,500.25
    -164.25 (-0.93%)
     

  • VOLATILITY

    16.17
    +0.20 (+1.25%)
     

  • FTSE

    8,091.42
    +51.04 (+0.63%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6816
    -0.0003 (-0.04%)
     

GW Pharmaceuticals PLC (GWPH) Stock Sinks As Market Gains: What You Should Know

Zacks Equity Research

GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $133.24, moving -0.61% from the previous trading session. This change lagged the S&P 500's daily gain of 0.33%. Elsewhere, the Dow gained 0.43%, while the tech-heavy Nasdaq added 0.33%.

Prior to today's trading, shares of the company had gained 20.94% over the past month. This has outpaced the Medical sector's gain of 3.22% and the S&P 500's gain of 2.66% in that time.

Wall Street will be looking for positivity from GWPH as it approaches its next earnings report date. This is expected to be November 5, 2019. On that day, GWPH is projected to report earnings of -$0.85 per share, which would represent year-over-year growth of 69.2%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $88.26 million, up 3547.11% from the year-ago period.

Any recent changes to analyst estimates for GWPH should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

ADVERTISEMENT

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 1.63% higher within the past month. GWPH is currently sporting a Zacks Rank of #3 (Hold).

The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 90, which puts it in the top 36% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
GW Pharmaceuticals PLC (GWPH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.